肝癌患者血清sCD40/sCD40L的表达水平及与预后的关系
|
摘要
目的研究肝癌患者血清可溶性CD40(sCD40)和可溶性CD40配体(sCD40L)的表达水平及与预后的关系。方法选择2010年1月至2013年2月诊治的62例肝癌患者为病例组,同时期体检健康者50例为对照组。采用ELISA法检测2组血清sCD40和sCD40L水平,分析血清sCD40和sCD40L水平与肝癌患者临床病理特征的关系,分析血清sCD40和sCD40L水平与肝癌患者死亡和生存的关系。结果病例组血清sCD40和sCD40L水平显著高于对照组(P<0.05);血清sCD40和sCD40L水平与肝癌患者淋巴结转移和TNM分期有关(P<0.05),而与肿瘤分化程度、肿瘤直径无关(P>0.05);62例肝癌患者术后均随访5年,存活25例,死亡37例,总生存率40.32%,死亡组患者血清sCD40和sCD40L水平均显著高于存活组(P<0.05);sCD40高水平组患者5年生存率(35.48%)显著低于sCD40低水平组患者5年生存率(83.87%)(P<0.05);sCD40L高水平组患者5年生存率(45.16%)显著低于sCD40L低水平组患者5年生存率(74.19%)(P<0.05)。结论肝癌患者血清sCD40和sCD40L水平明显升高,其水平越高,患者病情越严重,死亡风险越高,提示血清sCD40和sCD40L升高与肝癌患者不良预后有关,可用于临床评估肝癌预后。
Objective To investigate the expression of soluble CD40(sCD40),CD40 ligand(sCD40 L) and its relationship with prognosis of patients with liver cancer.Methods Sixty-two patients with liver cancer who were diagnosed and treated in our hospital from January 2010 to February 2013 were enrolled in observation group, at the same time, 50 healthy subjects who underwent physical examination were enrolled as control group. ELISA was used to detect the serum levels of sCD40 and sCD40 L of all subjects. Moreover, the relationship between the levels of sCD40. sCD40 L and clinicopathological characteristics of the patients was analyzed. In addition, the relationship between the levels of sCD40. sCD40 L and death, survival of the patients was analyzed.Results The serum levels of sCD40 and sCD40 L in observation group were significantly higher than those in control group(P<0.05), which were correlated with lymph node metastasis and TNM staging,however,which were not related to the degree of tumor differentiation and tumor diameter(P>0.05).After 5-year follow up in 62 patients with liver cancer after operation,25 cases were survived and 37 cases died, with the overall survival rate being 40.32%. The serum levels of sCD40 and sCD40 L in death group were significantly higher than those in survival group(P<0.05). Moreover, the 5-year survival rate of the patients with higher levels of sCD40(35.48%) was significantly lower than that of patients with lower levels of sCD40(83.87%)(P<0.05). The 5-year survival rate of the patients with higher levels of sCD40 L(45.16%) was significantly lower than that of patients with lower levels of sCD40 L(74.19%)(P<0.05).Conclusion The serum levels of sCD40 and sCD40 L of patients with liver cancer are increased significantly. The risk of death increases with the increase of the levels. The increase of the levels is associated with poor prognosis of patients, which can be used to evaluate the prognosis of patients with liver cancer in clinical practice.
Objective To investigate the expression of soluble CD40(sCD40),CD40 ligand(sCD40 L) and its relationship with prognosis of patients with liver cancer.Methods Sixty-two patients with liver cancer who were diagnosed and treated in our hospital from January 2010 to February 2013 were enrolled in observation group, at the same time, 50 healthy subjects who underwent physical examination were enrolled as control group. ELISA was used to detect the serum levels of sCD40 and sCD40 L of all subjects. Moreover, the relationship between the levels of sCD40. sCD40 L and clinicopathological characteristics of the patients was analyzed. In addition, the relationship between the levels of sCD40. sCD40 L and death, survival of the patients was analyzed.Results The serum levels of sCD40 and sCD40 L in observation group were significantly higher than those in control group(P<0.05), which were correlated with lymph node metastasis and TNM staging,however,which were not related to the degree of tumor differentiation and tumor diameter(P>0.05).After 5-year follow up in 62 patients with liver cancer after operation,25 cases were survived and 37 cases died, with the overall survival rate being 40.32%. The serum levels of sCD40 and sCD40 L in death group were significantly higher than those in survival group(P<0.05). Moreover, the 5-year survival rate of the patients with higher levels of sCD40(35.48%) was significantly lower than that of patients with lower levels of sCD40(83.87%)(P<0.05). The 5-year survival rate of the patients with higher levels of sCD40 L(45.16%) was significantly lower than that of patients with lower levels of sCD40 L(74.19%)(P<0.05).Conclusion The serum levels of sCD40 and sCD40 L of patients with liver cancer are increased significantly. The risk of death increases with the increase of the levels. The increase of the levels is associated with poor prognosis of patients, which can be used to evaluate the prognosis of patients with liver cancer in clinical practice.
引文
1 Qi C,Tian S,Wang J,et al.Co-expression of CD40/CD40L On XG1 Multiple Myeloma Cells Promotes IL-6 Autocrine Function.Cancer Investigation,2015,33:6-15.
2 叶珩,戚春建,钱科卿.CD40-CD40配体对胃癌细胞AGS增殖和侵袭作用研究.中华肿瘤防治杂志,2014,21:1697-1700.
3 Huang J,Jochems C,Talaie T,et al.Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role.Blood,2012,120:3030-3038.
4 Meng Z,Weixia L,Zhifa W,et al.Macrophages enhance tumor-derived autophagosomes(DRibbles)-induced B cells activation by TLR4/MyD88 and CD40/CD40L.Experimental Cell Research,2015,331:320-330.
5 沈笑春,雷伟,陈延斌,等.肺癌患者血浆CD62P、血清sCD40/sCD40L水平的检测及临床意义.中国血液流变学杂志,2013,23:631-634.
6 张亚衡,吴水英.血清可溶性CD30和CD40受体及配体异常表达与卵巢肿瘤的相关性.免疫学杂志,2013,29:642-644.
7 中国抗癌协会肝癌专业委员会.原发性肝癌规范化诊治的专家共识.临床肝胆病杂志,2009,17:295-304.
8 世界卫生组织,全球癌症报告.抗癌,2015,28:44-45.
9 Bishayee A.The role of inflammation and liver cancer.Adv Exp Med Biol,2014,816:401-435.
10 李佳红,付娜,牛学敏,等.573例原发性肝癌病因及临床特点分析.实用肝脏病杂志,2015,18:399-402.
11 Elgueta R,Benson MJ,Vries VCD,et al.Molecular mechanism and function of CD40/CD40L engagement in the immune system.Immunol Rev,2010,229:152-172.
12 周红霞.重症肝炎患者与原发性肝癌患者血清可溶性CD40表达水平研究.中国肝脏病杂志:电子版,2016,8:97-101.
13 Shen HH,Bai BK,Wang YQ,et al.Serum soluble CD40 is associated with liver injury in patients with chronic hepatitis B.Experimental Therapeutic Medicine,2015,9:999-1005.
14 Mu CY,Qin PX,Qu QX,et al.Soluble CD40 in plasma and malignant pleural effusion with non-small cell lung cancer:A potential marker of prognosis.Chronic Dis Transl Med,2015,1:36-41.
15 Nagasawa M,Zhu Y,Isoda T,et al.Analysis of serum soluble CD40 ligand(sCD40L) n the patients undergoing allogeneic stem cell transplantation:platelet is a major source of serum sCD40L.European Journal of Haematology,2015,74:54-60.
16 Jenabian MA,Patel M,Kema I,et al.Soluble CD40-ligand(sCD40L,sCD154) lays an immunosuppressive role via regulatory T cell expansion in HIV infection.Clinical Experimental Immunology,2015,178:102-111.
17 Chung HW,Lim JB.Clinical significance of elevated serum soluble CD40 ligand levels as a diagnostic and prognostic tumor marker for pancreatic ductal adenocarcinoma.J Transl Med,2014,12:102-111.
18 Younes A,Snell V,Consoli U,et al.Elevated levels of biologically active soluble CD40 ligand in the serum of patients with chronic lymphocytic leukaemia.Br J Haematol,2015,100:135-141.
19 Kedar R,Sabag O,Licthenstein M,et al.Soluble CD40 ligand(sCD40- L) rovides a new delivery system for targeted treatment:sCD40L-caspase 3 chimeric protein for treating B-cell malignancies.Cancer,2012,118:6089-6104.
2 叶珩,戚春建,钱科卿.CD40-CD40配体对胃癌细胞AGS增殖和侵袭作用研究.中华肿瘤防治杂志,2014,21:1697-1700.
3 Huang J,Jochems C,Talaie T,et al.Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role.Blood,2012,120:3030-3038.
4 Meng Z,Weixia L,Zhifa W,et al.Macrophages enhance tumor-derived autophagosomes(DRibbles)-induced B cells activation by TLR4/MyD88 and CD40/CD40L.Experimental Cell Research,2015,331:320-330.
5 沈笑春,雷伟,陈延斌,等.肺癌患者血浆CD62P、血清sCD40/sCD40L水平的检测及临床意义.中国血液流变学杂志,2013,23:631-634.
6 张亚衡,吴水英.血清可溶性CD30和CD40受体及配体异常表达与卵巢肿瘤的相关性.免疫学杂志,2013,29:642-644.
7 中国抗癌协会肝癌专业委员会.原发性肝癌规范化诊治的专家共识.临床肝胆病杂志,2009,17:295-304.
8 世界卫生组织,全球癌症报告.抗癌,2015,28:44-45.
9 Bishayee A.The role of inflammation and liver cancer.Adv Exp Med Biol,2014,816:401-435.
10 李佳红,付娜,牛学敏,等.573例原发性肝癌病因及临床特点分析.实用肝脏病杂志,2015,18:399-402.
11 Elgueta R,Benson MJ,Vries VCD,et al.Molecular mechanism and function of CD40/CD40L engagement in the immune system.Immunol Rev,2010,229:152-172.
12 周红霞.重症肝炎患者与原发性肝癌患者血清可溶性CD40表达水平研究.中国肝脏病杂志:电子版,2016,8:97-101.
13 Shen HH,Bai BK,Wang YQ,et al.Serum soluble CD40 is associated with liver injury in patients with chronic hepatitis B.Experimental Therapeutic Medicine,2015,9:999-1005.
14 Mu CY,Qin PX,Qu QX,et al.Soluble CD40 in plasma and malignant pleural effusion with non-small cell lung cancer:A potential marker of prognosis.Chronic Dis Transl Med,2015,1:36-41.
15 Nagasawa M,Zhu Y,Isoda T,et al.Analysis of serum soluble CD40 ligand(sCD40L) n the patients undergoing allogeneic stem cell transplantation:platelet is a major source of serum sCD40L.European Journal of Haematology,2015,74:54-60.
16 Jenabian MA,Patel M,Kema I,et al.Soluble CD40-ligand(sCD40L,sCD154) lays an immunosuppressive role via regulatory T cell expansion in HIV infection.Clinical Experimental Immunology,2015,178:102-111.
17 Chung HW,Lim JB.Clinical significance of elevated serum soluble CD40 ligand levels as a diagnostic and prognostic tumor marker for pancreatic ductal adenocarcinoma.J Transl Med,2014,12:102-111.
18 Younes A,Snell V,Consoli U,et al.Elevated levels of biologically active soluble CD40 ligand in the serum of patients with chronic lymphocytic leukaemia.Br J Haematol,2015,100:135-141.
19 Kedar R,Sabag O,Licthenstein M,et al.Soluble CD40 ligand(sCD40- L) rovides a new delivery system for targeted treatment:sCD40L-caspase 3 chimeric protein for treating B-cell malignancies.Cancer,2012,118:6089-6104.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |